MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
IBRX Cash Flow Sankey Diagram
Sankey diagram visualizing IBRX cash flow for the period
Proceeds from equity
offerings, net of issuance...
$147,275K
(-14.94%↓ Y/Y)
Proceeds from exercises
of stock...
$1,637K
Net cash provided by
financing activities
$44,443K
(-74.28%↓ Y/Y)
Canceled cashflow
$104,469K
Net change in cash
and cash...
-$129,523K
(-268.22%↓ Y/Y)
Canceled cashflow
$44,443K
Proceeds from maturities
of marketable debt...
$40,300K
Proceeds from sales of
marketable debt...
$19,986K
Change in fair value of
related-party convertible...
-$95,964K
(-8309.07%↓ Y/Y)
Change in fair value of
warrant liabilities
$44,190K
(1236.28%↑ Y/Y)
Non-cash interest
expense related to...
$11,281K
(12.60%↑ Y/Y)
Accrued expenses and
other liabilities
$8,563K
(-1.83%↓ Y/Y)
Stock-based compensation
expense
$8,518K
(-11.71%↓ Y/Y)
Depreciation and
amortization
$4,407K
(13.58%↑ Y/Y)
Inventories
-$1,014K
(43.79%↑ Y/Y)
Non-cash lease expense
related to operating...
$998K
(10.28%↑ Y/Y)
Prepaid expenses and
other current...
-$866K
(-121.99%↓ Y/Y)
Non-cash lease expense
related to operating...
$765K
(12.83%↑ Y/Y)
Prepaid expenses and
other current...
-$723K
(-452.68%↓ Y/Y)
Change in fair value of
derivative liabilities
$692K
(135.84%↑ Y/Y)
Due to and due from
related parties, net
$595K
(8600.00%↑ Y/Y)
Other assets
-$336K
(72.62%↑ Y/Y)
something is missing
-$103,198K
Principal payments on
premium financing
$886K
Net share
settlement for rsus vesting
$319K
(-0.93%↓ Y/Y)
Proceeds from the ripa,
net of issuance...
-$54K
Principal payments of
finance leases
$12K
(200.00%↑ Y/Y)
Net cash used in
investing activities
-$107,469K
(-565.77%↓ Y/Y)
Net cash used in
operating activities
-$66,494K
(16.62%↑ Y/Y)
Canceled cashflow
$60,286K
Canceled cashflow
$178,912K
Effect of exchange rate
changes on cash and cash...
-$3K
(-103.95%↓ Y/Y)
Purchases of marketable
debt securities,...
$164,216K
(990.34%↑ Y/Y)
Net loss
-$230,390K
(-148.87%↓ Y/Y)
Purchases of property,
plant and equipment
$3,516K
(225.25%↑ Y/Y)
Software development
costs
$23K
Accounts receivable
$10,201K
(100.14%↑ Y/Y)
Accretion of discounts on
marketable debt...
$2,272K
(20554.55%↑ Y/Y)
Operating lease
liabilities-Nonrelated Party
-$1,084K
(-9.27%↓ Y/Y)
Operating lease
liabilities-Related Party
-$978K
(-14.79%↓ Y/Y)
Accounts payable
-$247K
(96.03%↑ Y/Y)
Other
-$234K
(-210.90%↓ Y/Y)
Back
Back
ImmunityBio-logo-inverted-svg-svg
ImmunityBio, Inc. (IBRX)
ImmunityBio-logo-inverted-svg-svg
Cash Flow
Quarterly Cash Flow Statement for the quarter ending in 2026-06-30
source: myfinsight.com
ImmunityBio, Inc. (IBRX)